2017
DOI: 10.1080/15532739.2017.1290566
|View full text |Cite
|
Sign up to set email alerts
|

Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
4
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 12 publications
1
4
0
Order By: Relevance
“…The documented effects on testosterone concentrations are in line with those of an earlier study by Fung et al ( 28 ), which was performed in a smaller cohort on participants using 25 mg and 50 mg of CPA. They showed that 25 mg of CPA was just as effective as 50 mg of CPA in lowering testosterone concentrations.…”
Section: Discussionsupporting
confidence: 90%
“…The documented effects on testosterone concentrations are in line with those of an earlier study by Fung et al ( 28 ), which was performed in a smaller cohort on participants using 25 mg and 50 mg of CPA. They showed that 25 mg of CPA was just as effective as 50 mg of CPA in lowering testosterone concentrations.…”
Section: Discussionsupporting
confidence: 90%
“…In men with advanced prostate cancer, CPA monotherapy increases the risk of VTE compared with orchiectomy or luteinizing hormone‐releasing hormone antagonists . Recent data suggest that low‐dose CPA (25 mg daily) may be just as effective as higher doses (50‐100 mg) at maintaining suppression of testosterone levels in transwomen; impact on thrombotic events and other adverse effects were not studied . Cyproterone acetate is not available in the United States or Japan.…”
Section: Case I: Mtfmentioning
confidence: 99%
“…30 Recent data suggest that low-dose CPA (25 mg daily) may be just as effective as higher doses (50-100 mg) at maintaining suppression of testosterone levels in transwomen; impact on thrombotic events and other adverse effects were not studied. 31 Cyproterone acetate is not available in the United States or Japan. Subtle differences in spironolactone and CPA effects on lipids and prolactin levels may result in the endocrinologist's choosing one over the other for the individual patient.…”
Section: Vte Risks With Mtf Hormonal Therapymentioning
confidence: 99%
“…5 Lower doses of cyproterone acetate result in adequate testosterone suppression. 47 Importantly, more adequate suppression of serum testosterone concentration has been associated with enhanced breast development as measured by Tanner stage. 10 Similarly, greater changes in body composition are seen in transgender adolescents treated with GnRHa monotherapy than after subsequent commencement of estradiol.…”
Section: Contribution From Testosterone Suppressionmentioning
confidence: 99%